X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (180) 180
female (167) 167
oncology (139) 139
breast cancer (113) 113
breast neoplasms - pathology (97) 97
middle aged (93) 93
breast neoplasms - drug therapy (88) 88
breast neoplasms - genetics (86) 86
adult (82) 82
aged (75) 75
cancer (71) 71
chemotherapy (58) 58
gene expression profiling (50) 50
prognosis (48) 48
neoadjuvant therapy (40) 40
antineoplastic combined chemotherapy protocols - therapeutic use (39) 39
gene expression regulation, neoplastic (38) 38
gene expression (34) 34
treatment outcome (34) 34
breast neoplasms - metabolism (33) 33
research (32) 32
therapy (32) 32
pathology (31) 31
physics (31) 31
biochemistry (30) 30
survival (30) 30
chemotherapy, adjuvant (29) 29
immunohistochemistry (29) 29
beer (28) 28
chemistry (28) 28
compositions or test papers therefor (28) 28
condition-responsive control in microbiological orenzymological processes (28) 28
enzymology (28) 28
measuring or testing processes involving enzymes, nucleicacids or microorganisms (28) 28
metallurgy (28) 28
microbiology (28) 28
mutation or genetic engineering (28) 28
preoperative chemotherapy (28) 28
processes of preparing such compositions (28) 28
spirits (28) 28
vinegar (28) 28
wine (28) 28
diagnosis (27) 27
neoplasm staging (27) 27
predictive value of tests (27) 27
carcinoma (26) 26
doxorubicin (26) 26
investigating or analysing materials by determining theirchemical or physical properties (26) 26
measuring (26) 26
testing (26) 26
aged, 80 and over (25) 25
tumors (25) 25
breast neoplasms - surgery (24) 24
oligonucleotide array sequence analysis (24) 24
biopsy, needle (23) 23
care and treatment (23) 23
genetic aspects (23) 23
cyclophosphamide (22) 22
expression (22) 22
metastasis (22) 22
paclitaxel (22) 22
surgery (22) 22
biomarkers (21) 21
biopsy (20) 20
disease-free survival (20) 20
trastuzumab (20) 20
breast (19) 19
breast neoplasms - diagnosis (19) 19
estrogen (19) 19
receptors, estrogen - metabolism (19) 19
gene-expression profiles (18) 18
neoadjuvant chemotherapy (18) 18
sensitivity (18) 18
biomarkers, tumor - analysis (17) 17
medicine & public health (17) 17
paclitaxel - administration & dosage (17) 17
receptor, erbb-2 - metabolism (17) 17
reproducibility of results (17) 17
breast neoplasms - mortality (16) 16
surgical adjuvant breast (16) 16
antineoplastic agents - therapeutic use (15) 15
information and communication technology [ict] specially adaptedfor specific application fields (15) 15
mutation (15) 15
pathological complete response (15) 15
sensitivity and specificity (15) 15
abridged index medicus (14) 14
apoptosis (14) 14
cytology (14) 14
doxorubicin - administration & dosage (14) 14
genes (14) 14
tamoxifen (14) 14
calculating (13) 13
clinical trials (13) 13
computing (13) 13
counting (13) 13
electric digital data processing (13) 13
patient outcomes (13) 13
receptor, erbb-2 - genetics (13) 13
recurrence (13) 13
research article (13) 13
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 2016, Volume 375, Issue 1, pp. 11 - 22
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2016, Volume 375, Issue 1, pp. 23 - 34
Journal Article
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2008, Volume 26, Issue 8, pp. 1275 - 1281
Journal Article
Annals of surgical oncology, ISSN 1534-4681, 2011, Volume 19, Issue 5, pp. 1508 - 1516
Journal Article
Proceedings of the National Academy of Sciences - PNAS, ISSN 1091-6490, 2010, Volume 107, Issue 22, pp. 10208 - 10213
PIK3CA mutations are reported to be present in approximately 25% of breast cancer (BC), particularly the estrogen receptor—positive (ER+) and... 
Datasets | Health outcomes | Prognosis | Cell lines | Breast cancer | Signatures | Gene expression | Genetic mutation | Tumors | Cancer | Gene expression profiling | PI3 kinase | MOLECULAR SUBTYPES | TYROSINE PHOSPHORYLATION | MULTIDISCIPLINARY SCIENCES | PTEN | 3-KINASE MUTATIONS | AKT | EXPRESSION PROFILES | TUMORS | INSULIN-RECEPTOR | PATHWAY | POOR-PROGNOSIS | gene expression profiling | Neoplasms, Hormone-Dependent - metabolism | Receptors, Estrogen - metabolism | Oligonucleotide Array Sequence Analysis | Humans | Multiprotein Complexes | Receptor, ErbB-2 - metabolism | DNA Primers - genetics | Gene Expression Profiling | Proto-Oncogene Proteins c-akt - genetics | Breast Neoplasms - metabolism | Mechanistic Target of Rapamycin Complex 1 | Neoplasms, Hormone-Dependent - genetics | Proteins | Antineoplastic Agents, Hormonal - therapeutic use | Base Sequence | Female | Sirolimus - therapeutic use | Signal Transduction | Breast Neoplasms - drug therapy | Phosphatidylinositol 3-Kinases - genetics | Transcription Factors - metabolism | Breast Neoplasms - genetics | Class I Phosphatidylinositol 3-Kinases | Antibiotics, Antineoplastic - therapeutic use | Tamoxifen - therapeutic use | Cell Line, Tumor | TOR Serine-Threonine Kinases | Mutation | Neoplasms, Hormone-Dependent - drug therapy | Receptors | Analysis | Estrogen | Genetic aspects | Research | Properties | Tamoxifen | Protein kinases | Health aspects | TOR protein | Transformation | Exons | Estrogens | AKT protein | Data processing | 1-Phosphatidylinositol 3-kinase | Signal transduction | Biological Sciences
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2010, Volume 28, Issue 28, pp. 4316 - 4323
Journal Article
by Shi, Leming and Campbell, Gregory and Jones, Wendell D and Campagne, Fabien and Wen, Zhining and Walker, Stephen J and Su, Zhenqiang and Chu, Tzu-Ming and Goodsaid, Federico M and Pusztai, Lajos and Shaughnessy, John D and Oberthuer, André and Thomas, Russell S and Paules, Richard S and Fielden, Mark and Barlogie, Bart and Chen, Weijie and Du, Pan and Fischer, Matthias and Furlanello, Cesare and Gallas, Brandon D and Ge, Xijin and Megherbi, Dalila B and Symmans, W Fraser and Wang, May D and Zhang, John and Bitter, Hans and Brors, Benedikt and Bushel, Pierre R and Bylesjo, Max and Chen, Minjun and Cheng, Jie and Cheng, Jing and Chou, Jeff and Davison, Timothy S and Delorenzi, Mauro and Deng, Youping and Devanarayan, Viswanath and Dix, David J and Dopazo, Joaquin and Dorff, Kevin C and Elloumi, Fathi and Fan, Jianqing and Fan, Shicai and Fan, Xiaohui and Fang, Hong and Gonzaludo, Nina and Hess, Kenneth R and Hong, Huixiao and Huan, Jun and Irizarry, Rafael A and Judson, Richard and Juraeva, Dilafruz and Lababidi, Samir and Lambert, Christophe G and Li, Li and Li, Yanen and Li, Zhen and Lin, Simon M and Liu, Guozhen and Lobenhofer, Edward K and Luo, Jun and Luo, Wen and McCall, Matthew N and Nikolsky, Yuri and Pennello, Gene A and Perkins, Roger G and Philip, Reena and Popovici, Vlad and Price, Nathan D and Qian, Feng and Scherer, Andreas and Shi, Tieliu and Shi, Weiwei and Sung, Jaeyun and Thierry-Mieg, Danielle and Thierry-Mieg, Jean and Thodima, Venkata and Trygg, Johan and Vishnuvajjala, Lakshmi and Wang, Sue Jane and Wu, Jianping and Wu, Yichao and Xie, Qian and Yousef, Waleed A and Zhang, Liang and Zhang, Xuegong and Zhong, Sheng and Zhou, Yiming and Zhu, Sheng and Arasappan, Dhivya and Bao, Wenjun and Lucas, Anne Bergstrom and Berthold, Frank and Brennan, Richard J and Buness, Andreas and Catalano, Jennifer G and Chang, Chang and Chen, Rong and Cheng, Yiyu and ... and MAQC Consortium
Nature biotechnology, ISSN 1546-1696, 2010, Volume 28, Issue 8, pp. 827 - 838